VivoSim Labs Disclosed Failure to Satisfy a Continued Listing Rule or Standard
VivoSim Labs said Nasdaq notified it on July 20, 2026 that it failed Nasdaq Listing Rule 5550(b)(1), which requires at least $2.5 million in stockholders’ equity, and it did not qualify under alternative standards. The company has 45 days to submit a compliance plan, with a possible extension to Jan. 16, 2027. Trading remains on Nasdaq under VIVS.
How this was made
The 30-second read
Why it matters
The company must submit a compliance plan within 45 days (until Sept 3, 2026), with a possible extension to Jan 16, 2027. Trading continues on Nasdaq under VIVS, but the compliance process is a time-bound catalyst.
Market read
This disclosure is actionable for position management due to explicit compliance deadlines and delisting-risk framing, even though trading is unaffected today.
What to watch
Traders should focus on what Nasdaq accepts in the compliance plan and whether the cited equity transactions are durable and properly documented, since the notice cites failure to meet the rule and lack of alternative-standard qualification.
Background
Nasdaq Listing Rule 5550(b)(1) requires at least $2.5 million in stockholders’ equity; failure can lead to delisting unless the issuer submits an acceptable compliance plan.
Ticker impact
Nasdaq notified VivoSim Labs it failed Listing Rule 5550(b)(1) equity requirement, triggering a compliance-plan deadline while trading continues on VIVS.
Elevated volatility around the compliance-plan submission and any subsequent Nasdaq updates; directional bias depends on the credibility of the plan.
This is a primary regulatory listing compliance disclosure with explicit timelines (45 days to submit a plan, possible extension), but no immediate trading halt or confirmed delisting outcome is stated.
Market effects
Microcap and early-stage issuers on Nasdaq may see read-across risk for listing-rule compliance monitoring.
Primarily US-listed Nasdaq listing-compliance dynamics.
Limited, unless the company’s compliance issues reflect broader funding or capital-structure stress in similar markets.
Counterpoint
Because the filing states stockholders’ equity is above $2.5 million due to Item 8.01 transactions, the compliance outcome may be manageable and the market may overreact to the notice.
Key entities
- companyVivoSim Labs, Inc.
Nasdaq-listed issuer that received a notice for failing the $2.5 million stockholders’ equity listing rule.
- regulator/venueNasdaq
Exchange that issued the listing-rule noncompliance notice and sets the compliance-plan deadlines.
